Project Grant R21DA062129
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500 to the University of Pittsburgh to conduct research on the effects of xylazine and opioids on prefrontal cortex inhibitory transmission. The research aims to understand xylazine's cell signaling profiles and interactions with opioids at the circuit level, as xylazine is becoming highly prevalent in illicit opioid supplies and poses an...
- This $197,024 federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports two multi-methods studies to characterize the impact of the veterinary tranquilizer xylazine on people who use drugs (PWUD) in North Carolina and Maine. The first study in North Carolina aims to describe PWUD's perceptions and experiences with xylazine and related complications, such as overdoses and skin ulcers, through surveys...
- This Project Grant award, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a cohort study to examine the epidemiology of xylazine use and associated adverse health outcomes among people who have injected drugs in the Baltimore, Maryland area. The $193,854 award, effective from September 1, 2025 to August 31, 2027, will support research aims focused on understanding the associations between xylazine use and three...
- This federal Project Grant award of $233,250 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to evaluate the prevalence of the illicit drug adulterant xylazine and investigate the etiology of xylazine-related invasive infections. The key products/services to be delivered through this 2-year project include: Active surveillance of the local illicit drug supply in St. Louis, Missouri, using mass spectrometry and microbiologic...
- The Project Grant award of $231,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research at the University of Rochester to determine if the drug xylazine and its metabolites act as agonists or positive allosteric modulators at the mu and kappa opioid receptors. Additional studies will investigate whether xylazine and its metabolites are agonists, antagonists, or inverse agonists at the sigma 1 and sigma 2 receptors....
- This Project Grant award, valued at $506,000.00 and provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research at the Scripps Research Institute to develop monoclonal antibodies that can block the mechanism of action and adverse effects of the drug xylazine. Xylazine has emerged as an adulterant in illicit drug mixtures, contributing to overdose deaths, and this research aims to create novel therapeutic...
- This Project Grant award for $423,708 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding will support research to investigate the effects of fentanyl-xylazine drug mixtures on cardiorespiratory function and subjective effects in rats. Specifically, the research aims to characterize how xylazine impacts fentanyl-induced changes in heart rate, blood pressure, temperature, and respiration, as well as determine if...
- This Project Grant award of $107,912 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports a mixed methods study to better understand prenatal polysubstance use in the United States. The research involves two components: 1) Conducting 20 qualitative interviews with pregnant or postpartum individuals engaged in polysubstance use to explore the biopsychosocial context of these behaviors, and 2) Utilizing the CDC Pregnancy...
- This $387,750 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research by Mercer University to investigate the molecular pharmacology of the drug xylazine and its effects on adrenoceptors. The research aims to assess xylazine's binding affinity and functional profiles at different adrenoceptor subtypes expressed in vascular smooth muscle cells, as well as directly test the hypothesis that...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,460.00 to Brown University to develop a rule-based natural language processing (NLP) algorithm to identify patients exposed to fentanyl adulterated or associated with the veterinary sedative xylazine (FAAX). The key products and services to be delivered include: 1) Conducting 20-24 in-depth interviews with people who use drugs in Rhode...
This federal Project Grant award of $246,727, provided by the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs), will fund a mixed-methods, prospective cohort study to better understand the prevalence and clinical impact of xylazine exposure among pregnant persons who use drugs (PPWUD) at the University of Pittsburgh. The study aims to comprehensively evaluate differences in healthcare utilization patterns and maternal, perinatal, and infant outcomes between PPWUD with and without xylazine exposure. The research will utilize electronic health records, urine toxicology testing, and quantitative and qualitative participant data to address this critical knowledge gap and inform strategies to support PPWUD and mitigate the risks of xylazine exposure. The award period is from September 1, 2025 to August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $246.7k | 8/28/25 |